• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Phico Therapeutics

edit

Phico Therapeutics is developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.

Phico’s patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. SASPject™ is a new class of antibiotic which could provide many advantages over conventional antibiotic classes.

Recent Milestones

edit

• 
  Phico Therapeutics received $1.63M (£1M) in Venture Round funding. (6/11/11)
  Posted 4/28/10 at 3:09am via co.uk
• 
  Phico Therapeutics — Phico Therapeutics announces Dr Anthony F. Martin as Board Chairman (10/26/10)
  Posted 11/30/10 at 3:39am via co.uk
• 
  Phico Therapeutics — Phico Therapeutics today announces the successful completion of a phase I trial showing that their new antibiotic, SASPject PT1.2 is safe and well tolerated in healthy human volunteers. Plans for a phase II trial to assess efficacy are already underway. (6/17/10)
  Posted 6/17/10 at 4:07am via ac.uk

Videos

Screenshots

edit

Above: Phico Therapeutics
Uploaded: 4/28/10

Sources

1. Investors show support of Phico Therapeutics by upping stake by £1m (businessweekly.co.uk) [edit]
Wellcome Trust Award-Winning Company Phico Therapeutics Announces Success of Safety and Tolerability Trial (wellcome.ac.uk) [edit]
As SASPject enters phase II Phico Therapeutics announces Dr Anthony F. Martin as Board Chairman (phicotherapeutics.co.uk) [edit]